Cardiology
Enlicitide Adds an Oral Option for Hypercholesterolemia
FDA approval makes enlicitide the first oral PCSK9 inhibitor for adults who need additional LDL-C lowering despite maximally tolerated statins, including those with heterozygous familial hypercholesterolemia.
Rayan Salih · August 17, 2026 · 6 min